Journal
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 11, Issue 1, Pages 17-25Publisher
TAYLOR & FRANCIS AS
DOI: 10.1586/ERM.10.109
Keywords
cellular immunity; CMV; IFN-gamma-release assay; immunocompromised host
Categories
Ask authors/readers for more resources
Cytomegalovirus (CMV) infection has historically been a major complication among immunocompromised patients, such as solid-organ and stem-cell transplant recipients and patients with advanced HIV infection. While the introduction of antiretroviral therapy has almost eradicated CMV infection in HIV-infected patients, CMV disease remains a significant problem in transplant recipients once antiviral prophylaxis is discontinued. QuantiFERON (R)-CMV allows the assessment of cellular immunity against CMV by detecting the production of IFN-gamma following in vitro stimulation with CMV antigens. Preliminary studies have shown a correlation between a lack of detectable cell-mediated immunity measured by the QuantiFERON-CMV assay and a higher incidence of CMV infection and disease in immunocompromised patients. Measurement of cell-mediated immunity against CMV appears to be a promising strategy to identify patients at highest risk for the development of CMV disease and, therefore, to individualize preventive strategies for CMV in transplant recipients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available